{"entity":{"type":"insider","cik":"0001821530","url":"/insider/0001821530","json_url":"/insider/0001821530.json","name":"Dulac Edward J III","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":21,"n_filings":17,"first":"2021-08-20","last":"2026-07-24","span_basis":"filed_date"},"name_variants":[{"name":"Dulac Edward J III","source":"filing","n_filings":17,"first_seen":"2021-08-20","last_seen":"2026-07-24"}],"transactions":[{"id":5785696,"accession":"0001193125-26-316279","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-316279","line_url":"/filing/0001193125-26-316279#line-1","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (EVP, Chief Financial Officer)","officer_title":"EVP, Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8111.0,"shares_display":"8,111","price_per_share":11.25,"price_display":"11.25","price_state":"stated","total_value":91248.75,"total_display":"91,248.75","shares_owned_after":148175.0,"shares_owned_after_display":"148,175","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-22","filed_date":"2026-07-24","scope":"insider"},{"id":5876693,"accession":"0001821530-26-000002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001821530-26-000002","line_url":"/filing/0001821530-26-000002#line-1","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (EVP, Chief Financial Officer)","officer_title":"EVP, Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4677.0,"shares_display":"4,677","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":84186.0,"total_display":"84,186.00","shares_owned_after":156286.0,"shares_owned_after_display":"156,286","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-02","filed_date":"2026-07-06","scope":"insider"},{"id":5929325,"accession":"0001193125-26-006275","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-006275","line_url":"/filing/0001193125-26-006275#line-1","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (EVP, Chief Financial Officer)","officer_title":"EVP, Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6379.0,"shares_display":"6,379","price_per_share":9.21,"price_display":"9.21","price_state":"stated","total_value":58750.59,"total_display":"58,750.59","shares_owned_after":99683.0,"shares_owned_after_display":"99,683","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-05","filed_date":"2026-01-07","scope":"insider"},{"id":4983542,"accession":"0000950170-25-098774","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-098774","line_url":"/filing/0000950170-25-098774#line-1","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (EVP, Chief Financial Officer)","officer_title":"EVP, Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7462.0,"shares_display":"7,462","price_per_share":14.02,"price_display":"14.02","price_state":"stated","total_value":104617.24,"total_display":"104,617.24","shares_owned_after":106062.0,"shares_owned_after_display":"106,062","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-23","filed_date":"2025-07-25","scope":"insider"},{"id":2415460,"accession":"0000950170-24-025992","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-025992","line_url":"/filing/0000950170-24-025992#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2447.0,"shares_display":"2,447","price_per_share":7.77,"price_display":"7.77","price_state":"stated","total_value":19013.19,"total_display":"19,013.19","shares_owned_after":101479.0,"shares_owned_after_display":"101,479","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-04","filed_date":"2024-03-05","scope":"insider"},{"id":3150946,"accession":"0000950170-24-008803","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-008803","line_url":"/filing/0000950170-24-008803#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1849.0,"shares_display":"1,849","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":9245.0,"total_display":"9,245.00","shares_owned_after":103926.0,"shares_owned_after_display":"103,926","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-29","filed_date":"2024-01-30","scope":"insider"},{"id":2733507,"accession":"0000950170-24-003647","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-003647","line_url":"/filing/0000950170-24-003647#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7028.0,"shares_display":"7,028","price_per_share":4.37,"price_display":"4.37","price_state":"stated","total_value":30712.36,"total_display":"30,712.36","shares_owned_after":105775.0,"shares_owned_after_display":"105,775","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-09","filed_date":"2024-01-10","scope":"insider"},{"id":2080239,"accession":"0000950170-24-000874","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-000874","line_url":"/filing/0000950170-24-000874#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5182.0,"shares_display":"5,182","price_per_share":3.66,"price_display":"3.66","price_state":"stated","total_value":18966.12,"total_display":"18,966.12","shares_owned_after":112803.0,"shares_owned_after_display":"112,803","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-02","filed_date":"2024-01-03","scope":"insider"},{"id":8441945,"accession":"0001209191-23-059103","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-059103","line_url":"/filing/0001209191-23-059103#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1585.0,"shares_display":"1,585","price_per_share":3.5,"price_display":"3.50","price_state":"stated","total_value":5547.5,"total_display":"5,547.50","shares_owned_after":117985.0,"shares_owned_after_display":"117,985","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-18","filed_date":"2023-12-19","scope":"insider"},{"id":8608719,"accession":"0001209191-23-046691","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-046691","line_url":"/filing/0001209191-23-046691#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4718.0,"shares_display":"4,718","price_per_share":2.8,"price_display":"2.80","price_state":"stated","total_value":13210.4,"total_display":"13,210.40","shares_owned_after":119570.0,"shares_owned_after_display":"119,570","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-18","filed_date":"2023-08-21","scope":"insider"},{"id":8703757,"accession":"0001209191-23-041607","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-041607","line_url":"/filing/0001209191-23-041607#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5182.0,"shares_display":"5,182","price_per_share":4.83,"price_display":"4.83","price_state":"stated","total_value":25029.06,"total_display":"25,029.06","shares_owned_after":124288.0,"shares_owned_after_display":"124,288","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-07-05","filed_date":"2023-07-06","scope":"insider"},{"id":8104436,"accession":"0001209191-23-002975","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-002975","line_url":"/filing/0001209191-23-002975#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7331.0,"shares_display":"7,331","price_per_share":5.24,"price_display":"5.24","price_state":"stated","total_value":38414.44,"total_display":"38,414.44","shares_owned_after":129470.0,"shares_owned_after_display":"129,470","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-10","filed_date":"2023-01-11","scope":"insider"},{"id":6657730,"accession":"0001209191-22-046929","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-046929","line_url":"/filing/0001209191-22-046929#line-2","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4703.0,"shares_display":"4,703","price_per_share":29.75,"price_display":"29.75","price_state":"stated","total_value":139914.25,"total_display":"139,914.25","shares_owned_after":137233.0,"shares_owned_after_display":"137,233","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-18","filed_date":"2022-08-19","scope":"insider"},{"id":6657727,"accession":"0001209191-22-046929","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-046929","line_url":"/filing/0001209191-22-046929#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":432.0,"shares_display":"432","price_per_share":30.41,"price_display":"30.41","price_state":"stated","total_value":13137.12,"total_display":"13,137.12","shares_owned_after":136801.0,"shares_owned_after_display":"136,801","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-18","filed_date":"2022-08-19","scope":"insider"},{"id":6776479,"accession":"0001209191-22-003168","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-003168","line_url":"/filing/0001209191-22-003168#line-2","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1380.0,"shares_display":"1,380","price_per_share":48.25,"price_display":"48.25","price_state":"stated","total_value":66585.0,"total_display":"66,585.00","shares_owned_after":109024.0,"shares_owned_after_display":"109,024","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-11","filed_date":"2022-01-13","scope":"insider"},{"id":6776474,"accession":"0001209191-22-003168","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-003168","line_url":"/filing/0001209191-22-003168#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":390.0,"shares_display":"390","price_per_share":49.16,"price_display":"49.16","price_state":"stated","total_value":19172.4,"total_display":"19,172.40","shares_owned_after":108634.0,"shares_owned_after_display":"108,634","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-11","filed_date":"2022-01-13","scope":"insider"},{"id":4437459,"accession":"0001209191-21-070768","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-070768","line_url":"/filing/0001209191-21-070768#line-2","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15977.0,"shares_display":"15,977","price_per_share":60.0,"price_display":"60.00","price_state":"stated","total_value":958620.0,"total_display":"958,620.00","shares_owned_after":110404.0,"shares_owned_after_display":"110,404","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-20","filed_date":"2021-12-21","scope":"insider"},{"id":4840576,"accession":"0001209191-21-058176","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-058176","line_url":"/filing/0001209191-21-058176#line-2","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19460.0,"shares_display":"19,460","price_per_share":62.53,"price_display":"62.53","price_state":"stated","total_value":1216833.8,"total_display":"1,216,833.80","shares_owned_after":52404.0,"shares_owned_after_display":"52,404","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-28","filed_date":"2021-09-30","scope":"insider"},{"id":4731668,"accession":"0001209191-21-052742","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-052742","line_url":"/filing/0001209191-21-052742#line-3","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1937.0,"shares_display":"1,937","price_per_share":87.9,"price_display":"87.90","price_state":"stated","total_value":170262.3,"total_display":"170,262.30","shares_owned_after":56076.0,"shares_owned_after_display":"56,076","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-19","filed_date":"2021-08-20","scope":"insider"},{"id":4731659,"accession":"0001209191-21-052742","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-052742","line_url":"/filing/0001209191-21-052742#line-2","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1474.0,"shares_display":"1,474","price_per_share":88.65,"price_display":"88.65","price_state":"stated","total_value":130670.1,"total_display":"130,670.10","shares_owned_after":54602.0,"shares_owned_after_display":"54,602","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-19","filed_date":"2021-08-20","scope":"insider"},{"id":4731654,"accession":"0001209191-21-052742","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-052742","line_url":"/filing/0001209191-21-052742#line-1","is_derivative":false,"issuer_cik":"0001434316","issuer_name":"FATE THERAPEUTICS INC","issuer_ticker":"FATE","issuer_name_source":null,"issuer_url":"/issuer/0001434316","owner_cik":"0001821530","owner_name":"Dulac Edward J III","owner_url":"/insider/0001821530","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":63.0,"shares_display":"63","price_per_share":90.0,"price_display":"90.00","price_state":"stated","total_value":5670.0,"total_display":"5,670.00","shares_owned_after":54539.0,"shares_owned_after_display":"54,539","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-19","filed_date":"2021-08-20","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":21,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":21,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":21},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001652130","name":"Intellia Therapeutics, Inc.","url":"/issuer/0001652130","role":"Officer (EVP, Chief Financial Officer)","n_filings":4,"first_seen":"2025-07-25","last_seen":"2026-07-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001434316","name":"FATE THERAPEUTICS INC","url":"/issuer/0001434316","role":"Officer (Chief Financial Officer)","n_filings":13,"first_seen":"2021-08-20","last_seen":"2024-03-05"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001821530","retrieved_at":"2026-08-21T08:34:48+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}